Page 2193 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 130 Acquired Disorders of Platelet Function 1943.e3

104. Fuller RW: Serotonin uptake inhibitors: uses in clinical therapy and in 129. Langdell RD, Adelson E, Furth FW, et al: Dextran and prolonged
laboratory research. Prog Drug Res 45:167–204, 1995. bleeding time; results of a sixty-gram, one-liter infusion given to one
105. Sauer WH, Berlin JA, Kimmel SE: Effect of antidepressants and their hundred sixty-three normal human subjects. J Am Med Assoc 166:346,
relative affinity for the serotonin transporter on the risk of myocardial 1958.
infarction. Circulation 108:32, 2003. 130. Weiss HJ: The effect of clinical dextran on platelet aggregation, adhe-
106. Tseng YL, Chiang ML, Huang TF, et al: A selective serotonin reuptake sion, and ADP release in man: in vivo and in vitro studies. J Lab Clin
inhibitor, citalopram, inhibits collagen-induced platelet aggregation Med 69:37, 1967.
and activation. Thromb Res 126:517, 2010. 131. de Jonge E, Levi M: Effects of different plasma substitutes on
107. Reikvam AG, Hustad S, Reikvam H, et al: The effects of selective blood coagulation: a comparative review. Crit Care Med 29:1261,
serotonin reuptake inhibitors on platelet function in whole blood and 2001.
platelet concentrates. Platelets 23:299, 2012. 132. Mishler JM: Synthetic plasma volume expanders–their pharmacology,
108. Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, et al: Decreased sero- safety and clinical efficacy. Clin Haematol 13:75, 1984.
tonin content and reduced agonist-induced aggregation in platelets of 133. Horne MK, III, Chao ES: Heparin binding to resting and activated
patients chronically medicated with SSRI drugs. J Affect Disord 136:99, platelets. Blood 74:238, 1989.
2012. 134. Salzman EW, Rosenberg RD, Smith MH, et al: Effect of heparin
109. Blardi P, De Lalla A, Leo A, et al: Serotonin and fluoxetine levels in and heparin fractions on platelet aggregation. J Clin Invest 65:64,
plasma and platelets after fluoxetine treatment in depressive patients. 1980.
J Clin Psychopharmacol 22:131, 2002. 135. Sobel M, McNeill PM, Carlson PL, et al: Heparin inhibition of von
110. Menys VC, Smith CC, Lewins P, et al: Platelet 5-hydroxytryptamine Willebrand factor-dependent platelet function in vitro and in vivo. J
is decreased in a preliminary group of depressed patients receiving Clin Invest 87:1787, 1991.
the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci 136. Fernandez F, N’guyen P, Van Ryn J, et al: Hemorrhagic doses of heparin
91:87, 1996. and other glycosaminoglycans induce a platelet defect. Thromb Res
111. Humphries JE, Wheby MS, VandenBerg SR: Fluoxetine and the bleed- 43:491, 1986.
ing time. Arch Pathol Lab Med 114:727, 1990. 137. Perrault C, Ajzenberg N, Legendre P, et al: Modulation by heparin
112. Pai VB, Kelly MW: Bruising associated with the use of fluoxetine. Ann of the interaction of the A1 domain of von willebrand factor with
Pharmacother 30:786, 1996. glycoprotein Ib. Blood 94:4186, 1999.
113. Alderman CP, Moritz CK, Ben Tovim DI: Abnormal platelet aggrega- 138. Coller BS: Platelets and thrombolytic therapy. N Engl J Med 322:33,
tion associated with fluoxetine therapy. Ann Pharmacother 26:1517, 1990.
1992. 139. Miles LA, Ginsberg MH, White JG, et al: Plasminogen interacts
114. Roose SP, Rutherford BR: Selective serotonin reuptake inhibitors and with human platelets through two distinct mechanisms. J Clin Invest
operative bleeding risk: a review of the literature. J Clin Psychopharmacol 77:2001, 1986.
36:704, 2016. 140. Adelman B, Michelson AD, Loscalzo J, et al: Plasmin effect on plate-
115. Sajan F, Conte JV, Tamargo RJ, et al: Association of Selective Serotonin let glycoprotein Ib-von Willebrand factor interactions. Blood 65:32,
Reuptake Inhibitors with Transfusion in Surgical Patients. Anesth Analg 1985.
123:21, 2016. 141. Loscalzo J, Vaughan DE: Tissue plasminogen activator promotes
116. Hanley GE, Smolina K, Mintzes B, et al: Postpartum Hemorrhage and platelet disaggregation in plasma. J Clin Invest 79:1749, 1987.
Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. 142. Schafer AI, Adelman B: Plasmin inhibition of platelet function and of
Obstet Gynecol 127:553, 2016. arachidonic acid metabolism. J Clin Invest 75:456, 1985.
117. Anglin R, Yuan Y, Moayyedi P, et al: Risk of upper gastrointestinal 143. Watabe A, Ohta M, Matsuyama N, et al: Characterization of plasmin-
bleeding with selective serotonin reuptake inhibitors with or without induced platelet aggregation. Res Commun Mol Pathol Pharmacol
concurrent nonsteroidal anti-inflammatory use: a systematic review and 96:341, 1997.
meta-analysis. Am J Gastroenterol 109:811, 2014. 144. Kimura M, Andersen TT, Fenton JW, et al: Plasmin-platelet interac-
118. Noordam R, Aarts N, Leening MJ, et al: Use of antidepressants and tion involves cleavage of functional thrombin receptor. Am J Physiol
the risk of myocardial infarction in middle-aged and older adults: a 271:C54–C60, 1996.
matched case-control study. Eur J Clin Pharmacol 72:211, 2016. 145. Winters KJ, Santoro SA, Miletich JP, et al: Relative importance of
119. Ahr DJ, Scialla SJ, Kimbali DB, Jr: Acquired platelet dysfunction thrombin compared with plasmin-mediated platelet activation in
following mithramycin therapy. Cancer 41:448, 1978. response to plasminogen activation with streptokinase. Circulation
120. White JG, Rao GH: Effects of a microtubule stabilizing agent on the 84:1552, 1991.
response of platelets to vincristine. Blood 60:474, 1982. 146. Penny WF, Ware JA: Platelet activation and subsequent inhibition by
121. Quintás-Cardama A, Han X, Kantarjian H, et al: Tyrosine kinase plasmin and recombinant tissue-type plasminogen activator. Blood
inhibitor-induced platelet dysfunction in patients with chronic myeloid 79:91, 1992.
leukemia. Blood 114:261, 2009. 147. Parise P, Hauert J, Iorio A, et al: Streptokinase and rt-PA activate
122. Kostos L, Burbury K, Srivastava G, et al: Gastrointestinal bleeding in platelets by a different way: implications on the rethrombosis rate after
a chronic myeloid leukaemia patient precipitated by dasatinib-induced their administration in myocardial infarction. J Lab Clin Med 125:212,
platelet dysfunction: case report. Platelets 26:809, 2015. 1995.
123. Levade M, David E, Garcia C, et al: Ibrutinib treatment affects col- 148. Quinton TM, Kim S, Derian CK, et al: Plasmin-mediated activation
lagen and von Willebrand factor-dependent platelet functions. Blood of platelets occurs by cleavage of protease-activated receptor 4. J Biol
124:3991, 2014. Chem 279:18434, 2004.
124. Kozek-Langenecker SA: The effects of drugs used in anaesthesia on 149. Maron DJ, Fazio S, Linton MF: Current perspectives on statins.
platelet membrane receptors and on platelet function. Curr Drug Targets Circulation 101:207, 2000.
3:247, 2002. 150. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl
125. Gibbs NM: The effect of anaesthetic agents on platelet function. coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712,
Anaesth Intensive Care 19:495, 1991. 2001.
126. Watala C, Boncler M, Golanski J, et al: Release of calcium and P-selectin 151. Shattil SJ, Anaya-Galindo R, Bennett J, et al: Platelet hypersensitivity
from intraplatelet granules is hampered by procaine. Thromb Res 94:1, induced by cholesterol incorporation. J Clin Invest 55:636, 1975.
1999. 152. Tandon N, Harmon JT, Rodbard D, et al: Thrombin receptors define
127. Zhang W, Liu J, Sun R, et al: Calpain activator dibucaine induces responsiveness of cholesterol-modified platelets. J Biol Chem 258:11840,
platelet apoptosis. Int J Mol Sci 12:2125, 2011. 1983.
128. Dalsgaard-Nielsen J, Gormsen J: Effects of halothane on platelet func- 153. Shrimpton CN, Borthakur G, Larrucea S, et al: Localization of the
tion. Thromb Haemost 44:143, 1980. adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is